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The feasibility of CTAD (a mixture of citrate, theophylline,
adenosine and dipyridamole) as a new anticoagulant for medical
laboratory use was studied prospectively. Whole blood anti-
coagulated with CTAD exhibited results very similar to those of
blood anticoagulated with EDTAon complete blood count and
automated white cell diﬀerential except for a slight decrease in
platelet count and mean platelet volume. Chemistry test data for
plasma obtained from CTAD whole blood were close to those
obtained for matched sera. Among coagulation tests, prothrombin
time, activated partial thromboplastin time and ﬁbrinogen con-
centrations were close to those obtained with citrate plasma. Based
on the results, CTAD was judged to be a good candidate as a new
anticoagulant.
Introduction
The modern medical laboratory consists of fully auto-
mated analysers, and in it various types of specimen
containers are processed with robotic systems [1]. Pa-
tients must supply a lot of blood to ﬁll such containers for
stable automated laboratory tests.
A recent trend in laboratory testing is to test multiple
items with a minimum amount of sample blood, although
the reality is often quite diﬀerent. To reduce sample
blood volume for laboratory testing, various kinds of
universal anticoagulants have been proposed, but most
are not satisfactory for universal use [2–5]. On the other
hand, CTAD, a mixture of sodium citrate, citric acid,
theophylline, adenosine and dipyridamole was ﬁrst de-
veloped for use in blood coagulation tests with less eﬀect
on coexisting platelets [6, 7].
CTAD blood can be used for coagulation tests. If a
haematology test, chemistry and coagulation test were
achieved simultaneously from one test tube in an auto-
mated laboratory test line, it would be very desirable for
patients, since whole blood anticoagulated with heparin
has been routinely used for rapid chemistry tests. In this
context, the use of CTAD blood was attempted for three
kinds of tests: haematology, chemistry and coagulation as
a pilot study.
Experimental
Anticoagulants
CTAD tubes were purchased from Becton-Dickinson
Japan (Tokyo, Japan). Vacuum blood collection tubes
containing EDTA-2K or sodium citrate were purchased
from Terumo Co. (Tokyo, Japan).
Specimens
Venous blood was obtained from adult healthy donors
(aged 25–47 years). Multiple specimens with or without
an anticoagulant were prepared with the same blood.
The specimens were left to stand for 1h at room
temperature and then centrifuged at 1300g for 20min
to obtain plasma or serum.
Haematology tests
Whole blood specimens (n ¼ 46 adult healthy donors
aged 25–45 years) were obtained under informed con-
sent. After blood withdrawal, all specimens were kept at
room temperature, and all experiments were completed
within 6h of collection. Haematology analysers, the SE-
9000 (Sysmex Corp., Kobe, Japan) and a CELL-DYN
4000 haematology system (Abbott Diagnostics, Chicago,
IL, USA), were used for complete blood count (CBC) to
obtain red blood cell count (RBC), white blood cell
count (WBC), whole blood haemaglobin (Hb), haema-
tocrit (Hct), mean cell volume (MCV), red cell size
distribution (RDW), platelet count (Plt) and automated
white cell diﬀerential.
Push-wedge slides were prepared manually and stained
with May–Giemsa as controls for evaluation of auto-
mated white cell diﬀerential.
Chemistry tests
Plasma from CTAD blood (n ¼ 6, adult healthy donors
aged 30–47 years) were analysed with a fully automated
Hitachi 7170 multiple analyser (Hitachi Co., Tokyo,
Japan). As controls, serum specimens were prepared.
The biochemical and electrolyte items to be measured
are shown in table 1.
Coagulation tests
Venous specimens were obtained from 21 adult healthy
donors (aged 25–45 years) in two kinds of blood collec-
tion tubes containing sodium citrate or CTAD. Sepa-
rated plasma was tested within 3h after blood collection.
Prothrombin time (PT), activated partial thromboplas-
tin time (APTT), thrombo test (TH-T) and ﬁbrinogen
concentration were measured with speciﬁc reagents and a
CA-6000 coagulation analyser (Sysmex).
Statistical analysis
Statistical analysis was performed using a simple regres-
sion analysis with Microsoft Excel 98.
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Automated haematology tests
CBC and automated white cell diﬀerential were com-
pared between CTAD blood and EDTA-2K blood. In
CTAD blood, the proportion of blood to the CTAD
solution was 9:1. Therefore, the values of items inﬂu-
enced by dilution were corrected and compared with
those values from EDTA blood. Data analyses (means,
distribution width and simple regression analysis, r for
counts and p are shown in tables 2a and 2b. The means
and ranges of all parameters determined from the CTAD
samples compared well with those from the EDTA
Table 1. Methods used for analysis of biochemical and electrolyte parameters.
Items Method
Total protein (TP) Biuret
Albumin (ALB) BCG (bromcresol green)
Total bilirubin (T-bil) alkalineazo bilirubin
Blood urea nitrogen (BUN) urease UV
Creatinine (CRE) alkaline picrate
Uric acid (UA) uricase peroxidase
Lactose dehydrogenase (LDH) Wroblewski–Ladue
Aspartate aminotransferase (AST) UV
Alanine aminotransferase (ALT) UV
Glucose (Glu) glucose oxidase
C-reactive protein (CRP) turbidimetric immunoassay
Sodium (Na) electrode method by Hitachi 710
Chlorine (Cl) electrode method by Hitachi 710
Potassium (K) electrode method by Hitachi 710
Table 2a. Correlation between complete blood count proﬁle parameters for EDTAand CTA D blood measured
with SE-9000.
EDTA: y* CTAD: x* y ¼ ax þ br p
RBC ( 10
6 ml
 1) 4.36 0.51 4.42 0.52 y ¼ 0:981x þ 0:020 0.994 <0.0001
Hb (gdl
 1) 13.3 1.51 13.4 1.60 y ¼ 0:945x þ 0:615 0.996 <0.0001
Hct (%) 40.0 4.26 40.8 4.38 y ¼ 0:967x þ 0:496 0.994 <0.0001
MCV (mm
3) 92.0 6.22 92.6 6.22 y ¼ 0:997x   0:288 0.997 <0.0001
RDW (%) 12.0 0.95 12.0 0.94 y ¼ 1:010x   0:087 0.994 <0.0001
Platelet ( 10
3 ml
 1) 22.9 7.66 21.0 7.17 y ¼ 1:044x þ 1:013 0.977 <0.0001
WBC ( 10
3 ml
 1) 6.28 1.92 6.24 1.91 y ¼ 0:999x þ 0:049 0.993 <0.0001
Neutrophil ( 10
3 ml
 1) 4.00 1.75 3.99 1.84 y ¼ 0:935x þ 0:267 0.981 <0.0001
Lymphocyte ( 10
3 ml
 1) 1.69 0.71 1.72 0.75 y ¼ 0:902x þ 0:144 0.957 <0.0001
Monocyte ( 10
3 ml
 1) 0.34 0.11 0.27 0.13 y ¼ 0:516x þ 0:198 0.618 <0.0001
Eosinophil ( 10
3 ml
 1) 0.21 0.20 0.23 0.21 y ¼ 0:895x þ 0:011 0.988 <0.0001
Basophil ( 10
3 ml
 1) 0.03 0.02 0.03 0.02 y ¼ 0:725x þ 0:012 0.606 <0.0001
n ¼ 46.
*Each value is the mean SD.
Table 2b. Correlation between complete blood count proﬁle parameters for EDTAand CTA D blood measured
with CD-4000.
EDTA: y* CTAD: x* y ¼ ax þ br p
RBC ( 10
6 ml
 1) 4.27 0.49 4.34 0.51 y ¼ 0:958x þ 0:116 0.989 <0.0001
Hb (gdl
 1) 12.9 1.43 13.1 1.47 y ¼ 0:961x þ 0:288 0.991 <0.0001
Hct (%) 40.2 4.16 40.9 4.30 y ¼ 0:954x þ 1:159 0.985 <0.0001
MCV (mm
3) 94.5 6.33 94.8 6.27 y ¼ 1:006x   0:828 0.997 <0.0001
RDW (%) 13.5 0.97 13.6 0.99 y ¼ 0:978x þ 0:161 0.991 <0.0001
Platelet ( 10
3 ml) 23.1 7.89 20.5 6.90 y ¼ 1:121x þ 1:950 0.981 <0.0001
WBC ( 10
3 ml) 6.62 1.99 6.62 2.05 y ¼ 0:964x þ 0:243 0.994 <0.0001
Neutrophil ( 10
3 ml) 3.94 1.68 3.95 1.74 y ¼ 0:960x þ 0:142 0.997 <0.0001
Lymphocyte ( 10
3 ml) 2.05 0.78 2.00 0.76 y ¼ 1:017x þ 0:019 0.988 <0.0001
Monocyte ( 10
3 ml) 0.41 0.16 0.44 0.17 y ¼ 0:740x þ 0:082 0.822 <0.0001
Eosinophil ( 10
3 ml) 0.21 0.20 0.20 0.19 y ¼ 1:047x   0:004 0.984 <0.0001
Basophil ( 10
3 ml) 0.01 0.01 0.02 0.04 y ¼ 0:090x þ 0:010 0.246 0.099
n ¼ 46.
*Each value is the mean SD.
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cyte counts. A good correlation was demonstrated for
platelet count, although the value was lower for CTAD
blood than for EDTA blood. CTAD blood showed no
morphological eﬀects on blood cells and no active
platelet aggregation on Giemsa-stained blood ﬁlms.
Automated chemistry tests
The blood needed dilution correction because the CTAD
solution was liquid and diluted blood. As shown in table
3, 13 of 15 biochemical and electrolyte items had
coeﬃcients of correlation between the serum and CTAD
groups >0.95, while the coeﬃcient of correlation for Na
and Cl were low, at 0.2 and 0.5, respectively, because
CTAD contains large amounts of sodium.
Automated coagulation tests
Three of ﬁve coagulation test items, PT, APTT and
ﬁbrinogen concentration, exhibited very high correlation
coeﬃcients >0.9 between CTAD plasma and citrate
plasma, although HEP-T and TH-T how low correlation
coeﬃcients of 0.79 and 0.67, respectively (table 4).
Discussion
In modern laboratory testing systems, various kinds of
specimens are required, such as serum and whole blood
anticoagulated with EDTA and sodium citrate, which
require much blood to obtain laboratory data, although
many researchers and patients also wish to decrease the
volume of sample blood for laboratory testing. Recently,
many reports have described universal anticoagulants for
the reduction of blood volume for laboratory tests.
CTAD was ﬁrst developed for coagulation tests to elim-
inate coexisting platelet eﬀects in platelet-poor plasma.
CTAD is now also used for the platelet factor 4 and  -
thromboglobulin assays. However, no consideration has
been made of its uses as a universal anticoagulant.
Reinhart et al. [8] ﬁrst tried to use CTAD blood for
haematological testing in a relatively small number of
cases, and they reported that no diﬀerence in haemato-
logical data produced by electronic particle counters was
observed between EDTA and CTAD blood. Tsuda et al.
[9] also tried to use CTAD blood for complete blood
count and automated white cell diﬀerential to prove its
eﬃcacy for haematological analysis. In this study, large
numbers of samples were investigated with two auto-
mated analyser systems based on diﬀerent methods. The
data for items related to RBC were similar to those in
Table 3. Correlation between biochemical and electrolyte items for serum and CTAD plasma.
Serum: y* CTAD plasma: x* y ¼ ax þ br
TP (gdl
 1) 7.0 0.98 6.9 0.92 y ¼ 1:045x   0:263 0.991
ALB (gdl
 1) 4.1 0.21 4.1 0.15 y ¼ 0:876x þ 0:482 0.983
T-Bi (mgdl
 1) 0.6 0.29 0.7 0.14 y ¼ 0:813x þ 0:065 0.987
BUN (mgdl
 1) 15.8 4.46 15.4 4.66 y ¼ 0:948x þ 1:150 0.995
CRE (mgdl
 1) 0.75 0.34 0.73 0.33 y ¼ 1:004x þ 0:016 0.999
UA (mgdl
 1) 4.8 1.6 4.9 1.7 y ¼ 0:922x þ 0:353 0.995
LDH (IUl
 1) 422 135 379 127 y ¼ 1:021x þ 34:53 0.960
AST (IUl
 1)3 4  16.0 31 11.3 y ¼ 0:764x þ 6:896 0.965
ALT (IUl
 1)3 4  16.4 34 16.0 y ¼ 1:017x þ 0:929 0.990
CK (IU l
 1) 135 115 126 108 y ¼ 1:064x þ 1:233 0.999
Glu (gdl
 1) 104 10.1 96 9.2 y ¼ 1:063x þ 1:955 0.962
CRP (mgml
 1) 0.3 0.51 0.3 0.47 y ¼ 1:078x   0:004 0.996
Na (mEql
 1Þ 143 2.26 177 2.48 { 0.053
Cl (mEql
 1) 107 2.8 96 4.2 y ¼ 0:336x þ 74:87 0.515
K (mEql
 1) 4.0 0.37 3.9 0.35 y ¼ 1:038x þ 0:020 0.980
*Each value is the mean SD.
{With no correlation.
Table 4. Correlation between coagulation test items for citrate versus CTAD plasma.
Citrate plasma: y* CTAD plasma: x* y ¼ ax þ br
PT (s) 11.4 1.98 10.9 1.75 y ¼ 1:058x   0:117 0.937
APTT (s) 38.6 5.35 39.0 5.83 y ¼ 0:889x þ 3:967 0.969
TH-T (s) 89 46.6 212 139 y ¼ 0:202x þ 37:74 0.670
HEP-T (%) 88 26.0 121 45.5 y ¼ 0:453x þ 33:16 0.792
Fibrinogen (mgdl
 1Þ 298 134 298 98.2 y ¼ 0:920x   10:68 0.923
n ¼ 20.
*Each value is the mean SD.
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19EDTA blood and CTAD blood. In RBC morphology,
CTAD blood exhibited a shift in shape toward echino-
cytes [8], but a high degree of correlation was observed in
our data for items associated with RBC, including RDW
between EDTA and CTAD. The data for items related to
WBC are similar for EDTA-2K blood and CTAD blood,
except for basophil count. It is thought that the relative
scarcity of basophils in normal blood samples is primarily
responsible for this. Platelet counts were somewhat lower
than those in the EDTA-2K, but this item has a good
correlation for CTAD samples and EDTA-2K samples.
CTAD blood is thus useful for analysis by automated
haematology analyser systems.
As described above, such CTAD blood is useful for
automated haematology tests. It would be desirable if
such blood could also be used for chemistry tests. We
therefore tried to use CTAD blood for a chemistry test
and compared it with the test data obtained from serum
specimens. The results were in good accordance with
chemistry tests. One of the demerits of CTAD blood is
that it cannot provide accurate data for sodium and
chlorine because the sodium ion is contained in the
CTAD solution itself.
In coagulation test items, PT, APTT and ﬁbrinogen
concentration exhibited very high correlation coeﬃcients
between CTAD plasma and citrate plasma. On the other
hand, HEP-T and TH-T exhibited relatively low corre-
lation, although these two items are not in common
usage. The results indicated that CTAD blood is useful
not only for coagulation and haematology tests, but also
for chemistry tests.
In conclusion, we found that CTAD is an excellent
candidate for a new anticoagulant usable for simul-
taneous evaluation of haematological, biochemical and
coagulation items in the routine laboratory.
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